Back
Lipocine 10K Form
Buy
57
LPCN
Lipocine
Last Price:
4.79
Seasonality Move:
15.04%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-11-08 | 10Q | LPCN/Lipocine Quarterly |
| 2023-08-10 | 10Q | LPCN/Lipocine Quarterly |
| 2023-05-11 | 10Q | LPCN/Lipocine Quarterly |
| 2022-11-09 | 10Q | LPCN/Lipocine Quarterly |
| 2022-08-08 | 10Q | LPCN/Lipocine Quarterly |
| 2022-05-09 | 10Q | LPCN/Lipocine Quarterly |
Receive LPCN News And Ratings
See the #1 stock for the next 7 days that we like better than LPCN
LPCN Financial Statistics
Sales & Book Value
| Annual Sales: | $-2.85M |
|---|---|
| Cash Flow: | $-2.03M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $3.83 |
| Price / Book: | 1.25 |
Profitability
| EPS (TTM): | -3.05000 |
|---|---|
| Net Income (TTM): | $-16.35M |
| Gross Margin: | $-13.03M |
| Return on Equity: | -58.82% |
| Return on Assets: | -54.58% |
Lipocine Earnings Forecast
Key Lipocine Financial Ratios
- The Research & Development expenses have been 4,527.55% of Revenue.
- The Interest Expense is 0.00% of Operating Income.
- Per Share Earnings over the last 13 years have been positive in 6 years.
Lipocine Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Pharmaceuticals |
| Sector: | Health Care |
| Current Symbol: | LPCN |
| CUSIP: | 53630X |
| Website: | lipocine.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 8.69 |
| Quick Ratio: | 8.39 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |